Patent intelligence · US
US 11826405
Neurotoxin compositions for use in treating headache
Neurotoxin compositions for use in treating headache
Patent details — US 11826405
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 28, 2023
- Expiration
- Nov 23, 2043
- Applicant
- Aeon Biopharma, Inc.
- Claims
- 30
- CPC classes
- A61K, A61K38/4893, A61P, A61P25/06
Quick answer
US 11826405 (Neurotoxin compositions for use in treating headache) is held by Aeon Biopharma, Inc.. Status: granted. Granted Nov 28, 2023. Expires Nov 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Aeon Biopharma, Inc.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K38/4893, A61P, A61P25/06, A61P25/16
More from Aeon Biopharma, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11911455
HPV therapeutic nucleic acid vaccine
granted -
US 9901606
Euglena lysate composition
granted -
US 9274109
Gut flora-derived extracellular vesicles, and method for searching for a disease model, vaccine, and candidate drug and for diagnosis using the same
granted -
US 9201072
Gut flora-derived extracellular vesicles, and method for searching for a disease model, vaccine, and candidate drug and for diagnosis using the same
granted -
US 9149542
Microvesicles derived from cell protoplast and use thereof
granted -
US 9084830
Microvesicles derived from cell protoplast and use thereof
granted -
US 8969653
Extracellular vesicles derived from gram-positive bacteria, and use thereof
granted
Frequently asked questions
What is US patent 11826405?
US 11826405 (Neurotoxin compositions for use in treating headache) is held by Aeon Biopharma, Inc.. Status: granted. Granted Nov 28, 2023. Expires Nov 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11826405?
Aeon Biopharma, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does US 11826405 expire?
Our index shows an expiration date of Nov 23, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.